Alembic Pharma Q1 FY27: Revenue Rs 2,150 cr, up 26% YoY

Revenue Growth 20pctEbitda Margin CompressionResults View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹805.05

prior close

₹821.10

announcement price

In-mkt

timing

Nifty Microcap 250market+0.4%+0.3% vs market

Pharmaceuticals peers, median of 165sector-0.0%+0.8% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.7

15m

-2.1

30m

-2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+0.4+0.3-0.0+0.8

Next day

+1.4+1.7-0.4+0.0+1.4

+3.7+2.1+1.6+0.2+3.6

+3.6+2.1+1.4+0.4+3.2

+3.6+2.1+1.5+0.6+3.0

+4.3+1.9+2.4+0.8+3.5

+3.2+2.4+0.8+0.4+2.8

15d

-0.0+3.0-3.0+0.5-0.5

+0.1+3.7-3.7+1.1-1.1

+3.3+1.6+1.8+2.0+1.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated revenue rose 25.7% YoY to Rs 2,149.77 cr (vs Rs 1,710.72 cr in Q1 FY26). Consolidated PAT grew 12.7% to Rs 173.07 cr. Standalone revenue grew 25% to Rs 1,868 cr and standalone PBT jumped about 49% to Rs 255.9 cr. Consolidated EBITDA margin compressed to 13.84% from 16.03% YoY. No exceptional items in the current quarter. Statutory auditor issued an unqualified review report on both consolidated and standalone results.

Likely market impact

Strong revenue growth but margin compression noted. Unqualified auditor report reassures investors on accounting quality.